Skip to main content
. 2022 Oct 25;305(3):512–525. doi: 10.1148/radiol.220585

Figure 4:

Images in a 63-year-old woman with extensive small cell lung cancer detected at screening CT. (A) Baseline whole-body PET scan (left) and fused axial PET/CT images (right) demonstrate fluorodeoxyglucose-avid right lower lobe nodule (arrowhead, whole-body PET scan) and mediastinal and hilar lymphadenopathy (fused axial image on top right) as well as left adrenal lesion (arrow, fused axial image on bottom right). First-line therapy with the programmed death-ligand 1 inhibitor atezolizimab was initiated. (B) Follow-up whole-body PET scan (left) and fused axial PET/CT images (right) obtained after four cycles of atezolizimab, carboplatin, and etoposide show significantly improved thoracic lymphadenopathy and resolution of right lower lobe nodule. However, the left adrenal metastasis (arrow) has progressed and was treated with radiation therapy.

Images in a 63-year-old woman with extensive small cell lung cancer detected at screening CT. (A) Baseline whole-body PET scan (left) and fused axial PET/CT images (right) demonstrate fluorodeoxyglucose-avid right lower lobe nodule (arrowhead, whole-body PET scan) and mediastinal and hilar lymphadenopathy (fused axial image on top right) as well as left adrenal lesion (arrow, fused axial image on bottom right). First-line therapy with the programmed death-ligand 1 inhibitor atezolizimab was initiated. (B) Follow-up whole-body PET scan (left) and fused axial PET/CT images (right) obtained after four cycles of atezolizimab, carboplatin, and etoposide show significantly improved thoracic lymphadenopathy and resolution of right lower lobe nodule. However, the left adrenal metastasis (arrow) has progressed and was treated with radiation therapy.